Table 2.
Baseline demographics and disease characteristics of all patients included in the analysis
| Baseline demographics and disease characteristics | Treatment group | ||
|---|---|---|---|
| Non-ertugliflozin (n = 1450) | Ertugliflozin 5 mg (n = 1716) | Ertugliflozin 15 mg (n = 1693) | |
| Age (years) | 57.8 (10.3) | 57.9 (10.2) | 57.8 (10.2) |
| Male, n (%) | 787 (54.3%) | 885 (51.6%) | 844 (49.9%) |
| Body weight (kg)a | 89.2 (21.3) | 89.1 (20.8) | 87.5 (19.3) |
| BMI (kg/m2) | 31.6 (6.3) | 31.9 (6.1) | 31.5 (5.8) |
| Duration of T2DM (years) | 7.8 (6.3) | 7.9 (6.5) | 8.0 (6.3) |
| HbA1c (%)b | 8.1 (0.9) | 8.2 (0.9) | 8.2 (0.9) |
| ALT (IU/L)c | 26.6 (14.0) | 27.4 (14.6) | 27.6 (16.1) |
| AST (IU/L)d | 21.7 (9.4) | 22.0 (9.8) | 22.3 (10.4) |
| FIB-4e | 1.12 (0.56) | 1.11 (0.57) | 1.10 (0.53) |
| Platelet count (109/L)f | 239.2 (61.2) | 241.6 (60.4) | 245.1 (62.0) |
Data are presented as the mean with the standard deviation (SD) in parenthesis, unless otherwise specified
ALT Alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, FIB-4 Fibrosis-4 Index, HbA1c glycated hemoglobin, T2DM type 2 diabetes mellitus
a–fn is the number of patients in the non-ertugliflozin, ertugliflozin 5 mg, and ertugliflozin 15 mg treatment arms, respectively. an = 1442, n = 1706, and n = 1686; bn = 1439, n = 1695, and n = 1679; cn = 1417, n = 1677, and n = 1664; dn = 1415, n = 1672, and n = 1664; en = 1377, n = 1626, and n = 1621; fn = 1407, n = 1657, and n = 1651